www.cognitotx.com Open in urlscan Pro
185.212.71.195  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Close

Home About Us Our Platform Latest Publications

Click below to participate in our clinical studies

See all


HOPE STUDY

Mild-to-moderate Alzheimer's

Learn more



Clinical Studies

Menu



We recently started enrollment for our HOPE study for Alzheimer’s Disease. To
learn more click here!




HARNESSING THE BRAIN’S RESTORATIVE POWER

Every day at Cognito I am inspired by our potential to help millions of patients
living with neurodegenerative diseases via our breakthrough medical device.
Building on three decades of MedTech experience, this is the most rewarding
chapter of my career.

Kim Kwan, VP of Engineering

In my 20+ years in clinical research, I have never been more hopeful about a
treatment. This novel treatment has the potential to dramatically improve
outcomes for people worldwide who are suffering from the devastating impact of
Alzheimer’s disease

Celine Houser, VP of Clinical Operations

Having worked on the foundational science underlying many of today’s leading
Alzheimer’s treatments, I’m incredibly excited by the potential of Cognito’s
novel mechanism and the promise of fundamentally changing the trajectory of the
disease

Mihály Hajós, Chief Scientific Officer

I spent a substantial part of my career at some of the largest tech and medical
device companies in the world. But at Cognito, I’m honored to have the chance to
bring a novel product to patients who could realize a much-needed boosts to how
we treat a devastating disease like Alzheimer's

Jennifer Newberger, VP of Regulatory & Compliance
Participate
01


MISSION & VISION

We’re advancing the field of neuromodulation to create novel therapeutics that
improve the lives of patients living with neurodegenerative diseases.

Our CEO Brent Vaughan’s recent fireside chat at the CNS Summit about
game-changing neurotech to improve human cognition.



Our Novel Platform


INTRODUCING OUR NOVEL PLATFORM FOR NEURODEGENERATIVE DISEASE

Our investigational medical device delivers non-invasive neuromodulation with
the potential to improve outcomes in a range of neurodegenerative diseases,
including Alzheimer’s disease.

Learn More

OUR PIPELINE

Leveraging our platform across multiple neurodegenerative diseases.

Published Work

Focus

CogTx-001

ALZHEIMER’S DISEASE

CogTx-002

MCI - ALZHEIMER’S DISEASE

CogTx-003

PARKINSON’S DISEASE - DEMENTIA

CogTx-004

MULTIPLE SCLEROSIS

CogTx-005

ISCHEMIC STROKE

Discovery







Preclinical







Early Clinical







Pivotal Clinical







In market







LATEST NEWS & UPDATES


STAY UP TO DATE

Dec 1, 2022

STARTUP’S HEADSET TO TREAT ALZHEIMER’S WILL UNDERGO WIDE TRIAL WITH PATIENTS



Aug 3, 2022

COGNITO'S LIGHT-AND-SOUND THERAPY SLOWS BRAIN TISSUE ATROPHY IN ALZHEIMER'S
STUDY



May 2, 2022

SOME HEALTH APPS ARE ABLE NOT JUST TO DIAGNOSE DISEASES, BUT ALSO TO TREAT THEM



Apr 13, 2022

GAMMA SENSORY STIMULATION DEMONSTRATES EFFICACY IN ALZHEIMER DISEASE IN NEW
ANALYSIS


Read More

Home About Us Our Platform Latest Publications
Clinical Studies

1218 Massachusetts Ave,

Suite 200 Cambridge, MA 02138

857-201-5088

San Francisco Bay Area

857-201-5088

LinkedIn Twitter Inquiries? Contact us at info@cognitotx.com

Cognito Therapeutics © 2022